3984-14-3

Usage

Uses

1. Used in Chemical Synthesis:
N,N-Dimethylsulfamide is used as a reactant for the synthesis of various compounds, including N-sulfonylbenzaldimines in copper-catalyzed aza-Friedel-Crafts reactions with 1-methylindole. This application takes advantage of its versatile chemical properties to facilitate the formation of complex molecules.
2. Used in Environmental Chemistry:
N,N-Dimethylsulfamide is used as a precursor for carcinogenic Nitrosodimethylamine (N525625) upon ozonization. This application highlights its role in understanding the formation of harmful compounds in the environment and potentially developing methods to mitigate their formation or impact.

InChI:InChI=1/C2H8N2O2S/c1-4(2)7(3,5)6/h1-2H3,(H2,3,5,6)

Upstream product

• 13360-57-1 dimethylamino sulfonyl chloride 
• 29777-22-8 N,N-Dimethyl-N'-(trimethylsilyl)sulfamid 
• 124-40-3 dimethyl amine 

Downstream Products

• 7291-02-3 3-nitro-N,N-dimethylbenzamide 
• 18925-69-4 N,N-dimethyl-2-phenylacetamide 
• 127-19-5 N,N-dimethyl acetamide 
• 611-74-5 N,N-dimethylbenzamide 
• 14062-80-7 N,N-dimethyl-4-chlorobenzamide 
• 7291-01-2 N,N-dimethyl-4-nitrobenzamide 
• 1030-69-9 3-Dimethylaminosulfonyl-1-(4-dimethylamino-phenyl)-harnstoff 
• 188643-08-5 N,N-(dimethylsulfamoyl)benzaldimine 
• 124-40-3 dimethyl amine 
• 940939-32-2 (E)-N-(4-chlorobenzylidene)-N’,N’-dimethylsulfamide 

Relevant academic research and scientific papers

Photochemically Mediated Nickel-Catalyzed Synthesis of N-(Hetero)aryl Sulfamides

A general method for the N-arylation of sulfamides with aryl bromides is described. The protocol leverages a dual-catalytic system, with [Ir(ppy)2(dtbbpy)]PF6 as a photosensitizer, NiBr2·glyme as a precatalyst, and 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU)

SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors., method of making and pharmaceutical compositions comprising such compounds.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

N-AMINOSULFONYL BENZAMIDES

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulphonamide Nav 1.7 inhibitors of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z, R1a, R1b, R2, R3, R4 and R5 are as defined in the description. Nay 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.

Compounds useful for treating AIDS

The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS. The present invention further relates to compounds of formula (I) wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a -CN group, a -COORa group, a -NO2 group, a -NRaRb group, a -NRa-SO2-NRaRb group, a -NRa-SO2-Ra group, a -NRa-C(=O)-Ra group, a -NRa-C(=O)-NRaRb group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group, a -O-P(=O)-(ORc)(ORd) group, a -O-CH2-COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.

P′CP′-Pincer palladium complex-catalyzed allylation of N,N-dimethylsulfamoyl-protected aldimines

The P′CP′-pincer palladium complex-catalyzed allylation of N,N-dimethylsulfamoyl-protected aldimines with allyl(tributyl)stannane is investigated for the preparation of N-homoallylic sulfamides. The desired N,N-dimethylsulfamoyl-protected products are obt

Potassium channel openers

Compounds of formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

Potassium channel openers

Compounds of formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.